Key points are not available for this paper at this time.
The US Food and Drug Administration will leave most mobile medical applications unregulated while it focuses its oversight on apps that present the greatest risk of harming patients should they not work as intended, the agency said on Monday 23 September. “Some mobile apps carry minimal risks to consumers or patients, but others can carry significant risks if they do not operate correctly,” said Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, in a …
M. McCarthy (Thu,) studied this question.